A venture philanthropy firm located in Canada seeks to fund diagnostics and medical device companies that have a large social impact. The firm looks to invest early, even during conceptual stages. The firm’s main focus is on the entrepreneur. The firm typically invests between $2.5 million to $5 million in one company per year and remains highly involved throughout the development of the company. The firm will consider investing in companies located in North America.

The firm is interested in companies within the medical device or diagnostics space. The firm is both subsector and indication agnostic, looking instead at the social impact of the technology. Previous investments include two in vitro cancer diagnostics companies and a company developing a novel treatment for major depressive disorder. The firm will not consider investing in therapeutics.

The firm funds entrepreneurs first and ideas second. The firm looks for driven entrepreneurs and invests in them.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in New York is seeking to make seed, venture, and growth equity investments in early to mid-stage medical device companies. The firm can allocate anywhere from $1M to $10M per company, but generally allocates around $8M. The firm typically does 3 rounds of financing with an initial investment of around $3M. The firm is geographically agnostic, but highly prefers to invest in companies that are based in the US. The firm seeks to make about 3-4 allocations in the next 6-9 months.

The firm is currently looking for medical device companies with a strong emphasis on products with a 510(k) regulatory pathway. In terms of subsectors, the firm is looking for products specifically in the areas of interventional radiology and cardiology, spine/orthopedics and minimally invasive surgery. The firm is generally opportunistic in terms of indication.

The firm is looking to invest in companies with a management team with a track record of success in the healthcare industry. However, the firm is generally flexible and does not require a full management team. The firm can assemble the management team over the course of the investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A family office based in Boston, Massachusetts is currently interested in investing into privately held companies in the life science space. The firm is very flexible and nimble due to its capital base and is able to make investments ranging anywhere from $500,000 to $20 million and more into a given company. The firm is currently looking for companies located throughout the United States. The firm generally would only act as a co-investor from companies located outside the United States.

The firm is open to sectors and subsectors in the life science space including Health Care IT, Medical Devices, Diagnostics. For devices and diagnostics, the firm is looking for companies that have significant clinical data. Current portfolio companies include those working with antiviral therapies, cloud-based laboratory services, anticoagulant therapies, orthotics and prosthetics, medical devices and diagnostics for male lower urinary tract symptoms, and therapeutics for dermatology and aesthetics.

The firm is looking for companies with experienced management teams and generally looks to take a board seat following investment. Due to the firm’s capital base they can be more flexible in terms of investment timeframe and have a longer exit horizon than other investors.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in Shanghai, China currently manages two angel funds including RMB Fund I and Fund II, with a venture USD fund. On average, the initial size of investment is in the $1-6M range, but the firm has the capacity to invest more in companies they identify as a strong fit. The firm has multiple innovation centers across China focusing on different special areas in Life Sciences and Healthcare. With operating experience of international medical technology incubators, the firm looks to tailor its services to help portfolio companies reaching key value-added milestones. The firm will consider opportunities based in China and around the globe, companies within a strong China angle involvement is their sweet spot.

The firm is a flexible and opportunistic investor that is currently considering Therapeutics, Medical Devices, Diagnostics, Healthcare IT, and Biotechnology R&D Services. The firm is opportunistic in terms of subsector and indication and is willing to consider companies targeting orphan indications. The firm is open to novel medical devices of all FDA regulatory pathways, including 510k and PMA. In terms of therapeutics, the firm will look at products in pre-clinical stages. Regarding medical devices and diagnostics, the firm will invest at any stage of development.

The firm can participate as either lead or co-investor, and may take a board seat in applicable cases. The firm has no specific requirements for the management team. Team members who speak Mandarin may be a plus but are not required.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in Singapore with an additional office in the USA makes early up to expansion stage investments across several industries including healthcare. The investment size is highly variable depending on the stage of the company. The firm invests in companies in North America and Europe that has a market expansion strategy in Asia and/or Singapore. The firm is actively seeking new investment opportunities.

In the Life Sciences, the firm is currently seeking medical devices, synthetic biology and HCIT. For medical devices, the firm is opportunistic in terms of subsectors and indications. The firm looks for devices that are ready for commercialization. The firm is currently not looking for drug development companies.

The firm seeks entrepreneurs who are passionate, driven and enthusiastic, with sustainable business models and ideas.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A healthcare-focused venture capital firm manages 2 funds, a RMB denominated fund and a parallel USD fund. With the USD fund, the firm generally seeks to make equity investments into emerging life science companies in seed and venture stages; however, the fund also considers commercial-stage companies, depending on the opportunity. The investment size of the USD fund ranges from $5 – $25 million. For the RMB fund, typical investment size is RMB 30- RMB150 million. The firm currently focuses on China-based companies or overseas businesses with a China angle.

The firm is looking for new investment opportunities across a wide spectrum of life science sectors, including Therapeutics, Diagnostics, Biotech R&D Services, Medical Technology and Healthcare IT. The firm is agnostic to disease indications but is most interested in areas with large market potential, including Diabetes, Cardiovascular, Musculoskeletal System and Connective Tissue, Diseases of the Eye and Oncology. Rare diseases are generally less of interest. The firm is open to invest in both small molecules and biologics, and it looks for all classes of devices. The funds are most interested in companies in preclinical and early-clinical stage, but they are open to companies in late-clinical and growth stage, on a case-by-case basis.

The firm will only invest in private companies. The firm is looking to be an active investor, sometimes taking a board seat post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A VC fund based in the USA that was founded in 2016 invests in many sectors, including cloud based enterprise SaaS, Property Tech, and life sciences & healthcare. Within the life sciences, the firm is interested in therapeutics, medical device, digital health and healthcare IT companies. The firm generally invests in Series B and later rounds, and can invest anywhere from $1-20M in the initial check, and may participate in follow-on rounds. The firm is generally focused on investing in companies based in North America, but will consider global companies if they have a large presence in the US and are focused on the US market.

The firm will invest in therapeutics, medical device, digital health and healthcare IT companies. Within therapeutics, the firm is seeking companies in IND or later stages. In addition, the firm is interested in platform technologies, and will also invest in AI or machine learning based drug discovery companies. The firm will not invest in single asset or single modality companies. For medical devices, the firm primarily invests in 510K pathway devices that are FDA approved. The firm will not invest in DTC devices, and is less likely to consider de novo or PMA devices as well. Furthermore, the firm is most interested in devices that have a continuing source of revenue, such as a software application component. For digital health and healthcare IT companies, the firm is primarily focused on companies with B2B services, and will not invest in digital therapeutics. The firm is interested in companies that have greater than of $3M in ARR.

The firm is willing to lead or co-invest, but will generally take a board seat if they lead the investment round.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.